To confirm that compound 1 specifically binds to IGF-1R β and not to plasma membrane RTKs in general, the binding to EGFR, an RTK of relevance for NSCLC, was evaluated (Figure 5C–5D). This evidence concerns the gene EGFR and non-small cell lung carcinoma.